Tresiba® (Insulin Degludec) FlexTouch® Insulin Pens

What Is Tresiba® FlexTouch®?

Tresiba® FlexTouch® is a pre-filled, disposable insulin pen designed to deliver insulin degludec, an ultra-long-acting basal insulin analogue. It is indicated for the treatment of diabetes mellitus in adults, adolescents, and children (as per regional licensing approvals), and is used to maintain stable background insulin levels throughout the day and night.

Unlike traditional basal insulins with shorter durations of action, Tresiba provides glucose-lowering effects for more than 42 hours. This extended duration enables once-daily administration while reducing variability in insulin absorption and action. According to guidance from the National Institute for Health and Care Excellence (NICE), long-acting insulin analogues may be considered when improved glycaemic stability and reduced risk of nocturnal hypoglycaemia are desired.

The FlexTouch® pen device is engineered for ease of use, delivering accurate dosing without the need for vial-and-syringe preparation. This makes Tresiba particularly suitable for individuals seeking convenience, precision, and dependable insulin coverage.

How Tresiba® (Insulin Degludec) Works

Insulin degludec is structurally modified to form multi-hexamers upon subcutaneous injection. These multi-hexamers create a subcutaneous insulin depot that slowly and continuously releases insulin into the bloodstream. This mechanism results in:

• Consistent basal insulin levels over 24 hours and beyond
• Reduced peak-to-trough fluctuations
• Lower day-to-day variability compared with some other basal insulins

By facilitating glucose uptake into muscle and adipose tissue while suppressing hepatic glucose production, Tresiba helps maintain fasting and between-meal blood glucose control. Its stable pharmacokinetic profile contributes to a reduced risk of overnight hypoglycaemia, a common concern in insulin-treated patients.

In line with recommendations from the NHS guidance on diabetes management, maintaining stable background insulin levels is fundamental to preventing long-term complications such as neuropathy, nephropathy, and retinopathy.

Key Benefits of Tresiba® FlexTouch®

• Ultra-Long Duration: Effective glucose lowering for over 42 hours.
• Once-Daily Dosing: Simplifies insulin regimens for improved adherence.
• Flexible Dosing Time: Can be administered at different times of day, provided there is at least an 8-hour interval between doses.
• Reduced Nocturnal Hypoglycaemia Risk: Stable insulin release may lower overnight low blood sugar events.
• Precision Delivery System: FlexTouch® pen ensures accurate dosing in user-friendly format.
• Available in Two Strengths: 100 units/mL and 200 units/mL options.

The 200 units/mL concentration is particularly advantageous for individuals requiring higher daily insulin doses, as it allows delivery of larger doses in a smaller injection volume.

Indications and Clinical Use

Tresiba is indicated for:

• Adults with type 1 diabetes (used alongside rapid-acting mealtime insulin)
• Adults with type 2 diabetes requiring basal insulin therapy
• Paediatric patients, where licensed and prescribed by a specialist

For individuals with type 1 diabetes, Tresiba forms the basal component of a basal-bolus regimen. For those with type 2 diabetes, it may be used alone or in combination with oral antidiabetic medicines, GLP-1 receptor agonists, or mealtime insulin as clinically indicated.

Dosage and Administration

Available Strengths

• Tresiba® 100 units/mL FlexTouch®
• Tresiba® 200 units/mL FlexTouch®

Starting Dose

For insulin-naïve adults with type 2 diabetes, the usual starting dose is 10 units once daily. Dose adjustments should be individualised based on blood glucose monitoring results, dietary patterns, and clinical response.

Type 1 Diabetes

In type 1 diabetes, Tresiba must be combined with rapid-acting insulin to cover mealtime glucose excursions.

Flexible Dosing Guidance

Tresiba allows flexibility in dosing time, provided doses are separated by at least 8 hours. This feature supports adherence for individuals with irregular schedules, shift work, or travel commitments.

Injection Sites

• Abdomen
• Thigh
• Upper arm

Rotate injection sites within the same anatomical region to reduce the risk of lipodystrophy.

Step-by-Step: How to Use Tresiba® FlexTouch®

1. Check the Pen: Ensure the insulin solution is clear and colourless.
2. Attach a New Needle: Use a fresh needle for each injection.
3. Prime the Pen: Perform an air shot before each use.
4. Select the Dose: Turn the dose selector to the prescribed number of units.
5. Inject Subcutaneously: Insert the needle into the skin.
6. Hold for 6 Seconds: Keep the needle in place to ensure full dose delivery.
7. Dispose Safely: Remove and discard the needle in a sharps container.

Never share insulin pens, even if the needle is changed, due to infection risk.

Possible Side Effects

Common Side Effects

• Hypoglycaemia (low blood sugar)
• Injection site reactions
• Weight gain

Serious but Less Common Effects

• Severe hypoglycaemia requiring medical assistance
• Allergic reactions, including anaphylaxis
• Lipodystrophy

Seek immediate medical attention if severe allergic symptoms or persistent low blood sugar occur.

Drug Interactions

Tresiba may interact with:

• Oral antidiabetic agents (e.g., metformin, sulfonylureas)
• SGLT-2 inhibitors
• ACE inhibitors and ARBs
• Beta-blockers (may mask hypoglycaemia symptoms)

Inform your prescriber about all medications and supplements to minimise risks.

Precautions

• Renal or hepatic impairment
• Frequent hypoglycaemic episodes
• Pregnancy or breastfeeding

Close monitoring may be required in these circumstances.

Storage Instructions

• Unopened pens: Store refrigerated at 2°C–8°C.
• Do not freeze.
• After first use: Store below 30°C for up to 8 weeks.
• Protect from heat and direct sunlight.

Frequently Asked Questions

How long does Tresiba last once opened?

Opened pens may be used for up to 8 weeks when stored at room temperature below 30°C.

Can Tresiba be used for type 1 diabetes?

Yes, when combined with rapid-acting insulin for mealtime coverage.

Is Tresiba suitable for flexible schedules?

Yes. Provided there is an 8-hour interval between doses, timing flexibility is permitted.

Further Information

For comprehensive prescribing details, consult the official Tresiba® Product Monograph or speak with your healthcare provider.